<DOC>
	<DOCNO>NCT00447577</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy Zylet vs. Tobradex treatment ocular inflammation associate blepharokeratoconjunctivitis</brief_summary>
	<brief_title>Zylet v TobraDex Blepharokeratoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Must least 18 year age Must able willing comply treatment follow procedure Must ability understand sign Informed Consent Form provide Health Insurance Portability Accountability Act ( HIPAA ) authorization Must able selfadminister drug Must clinical diagnosis blepharokeratoconjunctivitis least one eye ( total Ocular Signs Symptoms score least 10 , least one ocular sign one ocular symptom score Grade 2 level high ) Women childbearing potential must sexually inactive use approved birth control method must negative urine pregnancy test Must willing discontinue contact lens use duration study Must pinholed Snellen visual acuity equal well 20/40 eye Any uncontrolled systemic disease debilitate disease ( e.g . cardiovascular disease , hypertension , diabetes , cystic fibrosis ) Known hypersensitivity study drug component ( include benzalkonium chloride ) contraindication tobramycin ocular corticosteroid Use systemic topical ophthalmic nonsteroidal antiinflammatory agent , analgesic , antihistamine discontinue study Use topical ophthalmic medication , include tear substitute , within 2 hour discontinue study Use systemic topical ophthalmic antibiotic agent within 72 hour discontinue study Use systemic topical ophthalmic corticosteroid agent within 7 day discontinue study Use systemic topical ophthalmic mast cell stabilizer within 14 day discontinue study Use topical ophthalmic immunosuppressant ( e.g . Restasis ) agent within 30 day discontinue study Suspected preseptal cellulite , disease condition Investigator determines could interfere safety efficacy evaluation study drug Suspected dacrocystitis Participation ophthalmic drug device research study within 30 day prior entry study Ocular surgery ( include laser surgery ) either eye within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>